Syndax Pharmaceuticals (SNDX) Non Operating Income (2015 - 2026)

Syndax Pharmaceuticals' Non Operating Income history runs 12 years deep, the most recent figure standing at -$186000.0 for Q1 2026.

• In Q1 2026, Non Operating Income rose 82.92% year-over-year to -$186000.0; the TTM figure through Mar 2026 stood at -$17.2 million (down 445.19% YoY), while the FY2025 annual figure was -$12.3 million, down 4895.14% from the prior year.
• Non Operating Income was -$186000.0 for Q1 2026 at Syndax Pharmaceuticals, up from -$11.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $7.1 million in Q1 2024 to a low of -$15.5 million in Q4 2023.
• Historically, Non Operating Income has averaged -$194588.2 across 5 years, with a median of -$106000.0 in 2024.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income jumped 3230.92% in 2023, then sank 10518.87% in 2025.
• A 5-year view of Non Operating Income shows it stood at $2.6 million in 2022, then plunged by 690.45% to -$15.5 million in 2023, then soared by 99.32% to -$106000.0 in 2024, then tumbled by 10518.87% to -$11.3 million in 2025, then jumped by 98.35% to -$186000.0 in 2026.
• The last three Non Operating Income figures came in at -$186000.0 (Q1 2026), -$11.3 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.